DCLK1 and colonic neoplasm: Mechanistic investigations in human colon cancer revealed that the 5’ (α) promoter is hypermethylated and epigenetically silenced, resulting in preferential activation of β-promoter and predominate upregulation of DCLK1-S variants [62].